Whilst there are ongoing phase 3 trials in patients with AF to assess the effectiveness of FXI inhibition in preventing thromboembolic complications, it was our aim to assess the existing available data from clinical trials regarding the comparative safety of FXI inhibitors in comparison to DOACs, in individuals with AF. This evidence concerns the gene F11 and atrial fibrillation.